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Abstract
The study of disease pathophysiology has long relied on model systems, including animal models 
and cultured cells. In 2006, Shinya Yamanaka achieved a breakthrough by reprogramming somatic 
cells into induced pluripotent stem cells (iPSCs). This revolutionary discovery provided new 
opportunities for disease modeling and therapeutic intervention. With established protocols, 
investigators can generate iPSC lines from patient blood, urine, and tissue samples. These iPSCs 
retain ability to differentiate into every human cell type. Advances in differentiation and 
organogenesis move cellular in vitro modeling to a multicellular model capable of recapitulating 
physiology and disease. Here, we discuss limitations of traditional animal and tissue culture 
models, as well as the application of iPSC models. We highlight various techniques, including 
reprogramming strategies, directed differentiation, tissue engineering, organoid developments, and 
genome editing. We extensively summarize current established iPSC disease models that utilize 
these techniques. Confluence of these technologies will advance our understanding of pediatric 
diseases and help usher in new personalized therapies for patients.
History of Disease Models
The optimal diagnosis and treatment of pediatric disease requires an understanding of 
physiology and pathophysiology. Throughout medical research history animal and cell 
culture models have been critical to this process. Mouse models, in particular, are 
extensively utilized because they are relatively convenient, and similar to humans at the 
chemical, molecular, cellular, and some anatomic levels. Furthermore, the use of transgenic 
mice allows for genetic manipulation to help elucidate molecular mechanisms. However, 
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given that mice and humans diverged millions of years ago, there are critical physiological 
differences between the two species (1).
Human diseases often lack a mice ortholog. The equivalent disease in mice may be fatal or 
benign, and we cannot model some high level human organ functions or late onset diseases. 
Even non-human primates, despite being our closest ancestors, have important phenotypic 
differences (2). For example, because of these differences, it is particularly difficult to 
develop animal models for neurodegenerative or neurodevelopmental disorders. Differences 
in mouse cardiac morphogenesis have led difficulty modeling human congenital heart 
disease (3, 4). These limitations drive the need for human cell, tissue, and organ systems 
models.
Many human diseases involve terminally differentiated cell types, such as neurons and 
cardiomyocytes. These cell types are nearly impossible to sample, culture, and maintain. 
Even after generating primary cell lines from diseased tissues, ability to derive meaningful 
conclusions is often hampered by inconsistent replicability, dedifferentiation, and variability 
due to culture conditions. Tissues derived from human induced pluripotent stem cells 
(iPSCs) has the potential to overcome many inherent limitations of animal and cell culture 
models and provide an unprecedented new paradigm to model human diseases.
Pluripotent Stem Cells
During human embryogenesis, the ovum and spermatozoa fuse at fertilization, begin to 
divide, and differentiate into all cell lineages and tissue types in the human body. During 
development, these cells lose their pluripotency as they terminally differentiate into specific 
cell types. Embryonic stem cells (ESC) were first isolated from the blastocyst of developing 
mouse embryos in 1981, and from human embryos in 1998(5–7). These cells have the 
remarkable ability to retain pluripotency. The ESC discovery generated great excitement 
over their potential applicability in human disease modeling and regenerative therapies. 
However, limitations and controversies soon emerged.
The isolation of ESCs from human embryos is ethically controversial. Disease models 
utilizing ESC are limited to diseases identified through preimplantation genetic diagnosis 
(8). Genome editing ECSs provides an opportunity to generate particular mutations of 
interest, but technique remains largely limited to monogenic diseases. Recent breakthroughs 
in induced pluripotent stem cell (iPSC) technology circumvent many of these drawbacks.
Induced Pluripotent Stem Cells
In 2006, Shinya Yamanaka identified four transcription factors, (OCT4, SOX2, KLF4, and c-
MYC), that were capable for reprogramming somatic mouse cells into a pluripotent state (9–
11). This extraordinary feat was recapitulated one year later in human cells. These induced 
pluripotent stem cells (iPSCs) behave like ESCs with capability to differentiate to most other 
cell types, and circumvent the ethical controversy and sample limitations. As opposed to 
human embryos, iPSCs can be generated from readily accessible tissue samples, such as 
peripheral blood mononucleated cells (PBMCs). Patient samples can be reprogrammed to 
iPSCs, serving as an autologous, continuously renewing supply of pluripotent cells.
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This has resulted in the dramatic expansion of the stem cell field, with development and 
improvements in reprogramming protocols and directed cellular differentiation. Patient-
specific iPSCs can be generated from wide variety of patient samples, including PBMCs 
from blood samples, to dermal fibroblasts from punch biopsies, and epithelial cells from 
urine samples. iPSCs can then be differentiated to most other cell types including 
cardiomyocytes, neurons, and hepatocytes. Because the lines are patient-specific, they are 
expected to recapitulate features of many disease phenotypes, whether due to simple 
monogenic mutations or complex polygenic disease susceptibilities. The patient-specific 
iPSCs hold potential for disease modeling, predicting drug response and assessing 
environmental triggers of diseases. Thus, they provide great potential for research and 
clinical applications in personalized medicine.
Gene Editing iPSCs
Mouse models allow genetic alteration using transgenesis and gene knock-outs. Measuring 
the resulting phenotype is extremely valuable in the study of genetics and development. 
iPSCs allow us to utilize these same genetic approaches using human cell lines. The past 
decade has seen tremendous advances in gene editing technology, including ZFNs (zinc 
finger nucleases), TALENs (transcription activator like effector nucleases), and CRISPR–
Cas9 (clustered regularly interspaced short palindromic repeat)(12–18). The common 
mechanism of these genomic editing approaches is that they create double stranded breaks 
(DSBs) at desired locations in the genome, which then can be repaired by either 
nonhomologous end-joining (NHEJ) that can result in insertion/deletions (indels) or 
homology directed repair (HDR), which results in precise gene modifications. Of these, the 
CRISPR-Cas9 technology, which appropriates the prokaryote defense mechanism, has 
quickly become dominant due to ease with which it can be adapted to precisely edit virtually 
any region in the host genome.
Genome editing, coupled with the iPSC technology, allow us to study disease mechanism 
like never before. These technologies allow us to precisely correct mutations and insert 
reporters under the endogenous regulatory control. They have also been used to demonstrate 
feasibility of genomic editing as a therapeutic modality (19, 20). Recently, a group corrected 
a pathogenic mutation in preimplantation human embryos, demonstrating the feasibility of 
gene correction therapy(21). While still a long way from clinical applications, many disease 
phenotypes have been corrected in cell culture. These studies show the potential of these 
powerful technologies for disease modeling, and for therapeutic genome engineering (Table 
1).
Choice of a Disease
While a wide variety of human diseases are amenable to iPSC modeling. iPSCs are 
particularly attractive for diseases without a useful animal or cell culture model. The disease 
expression must be cell autonomous, preferably with clearly defined cell or tissue specific 
phenotypes. However, even in cases without a readily apparent disease phenotype, disease-
specific iPSCs may be valuable for discovering gene networks and developmental programs 
altered in the disease state.
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When a disease is thought to arise from a single causal gene mutation (i.e. monogenic), 
genomic editing would suffice to recapitulate disease phenotype. However, many diseases 
are complex, with polygenic and heterogeneous inheritance patterns. In such cases, 
generation of iPSCs from affected patients accurately replicates this complexity. For 
multifactorial disease we must consider disease penetrance and variable expressivity. In 
some instances, a disease may have both monogenic as well as polygenic etiology, and 
iPSCs may be a valuable tool. For example, iPSCs from Alzheimer’s Disease patients have 
been valuable for modeling, and differentiating between, monogenic and polygenic 
etiologies (22). One must also consider the timing of disease onset. For congenital diseases, 
it may be informative to measure alternations in the development program during transition 
from the iPSC state to the terminal differentiated cell type. By contrast, diseases manifesting 
at a later age, or in adulthood, may require maturation techniques. Disease marked by 
disruption in a higher-level architecture may benefit from organoid models; three-
dimensional multi-cell type organoids are available for most organs.
Cell Maturity and Epigenetic Considerations
Early efforts at directed differentiation of iPSCs resulted in cell types that resembled 
embryonic tissues; but accurate modeling of adult-onset diseases ideally requires generation 
of cells with mature, rather than embryonic, characteristics. Typically, long term culture 
following induction of iPSC differentiation leads to a more mature phenotype. This strategy 
produces iPSC-derived cardiomyocytes (iPSC-CMs) with increased expression of 
maturation-associated markers (23, 24). Alternative approaches to promote maturation of 
iPSC-CMs toward phenotypes that better resemble adult cardiomyocytes utilize novel 
culture methods such as enriched ECM (25–27). To age neuronal cells in vitro, Rotenone, 
which produces oxidative stress, has been used inducing telomere shortening and increase 
senescence markers (28). Similar aging-associated changes, such as telomere shortening and 
cellular senescence, are inducible using Progerin, a protein associated with premature aging 
in humans (28). The effects of “epigenetic memory” on directed differentiation of iPSCs are 
incompletely appreciated, but there is evidence that, after a successful reprogramming, 
iPSCs retain some epigenetic signature of the origin cell type. For instance, iPSCs 
reprogrammed from pancreatic tissue samples appear to be more readily differentiated to 
pancreatic beta cells than other tissue types (29). The impact of the epigenetic memory on 
the final phenotype of cells differentiated from iPSCs requires further investigation.
Derivation of iPSC Disease Models
The process of iPSC generation begins with somatic cells growing in tissue culture (Figure 
1). A common source of somatic cells includes patient fibroblasts, obtained from skin punch 
biopsy, or postoperative tissue sample (11). More recent protocols derive iPSCs from patient 
samples obtained noninvasively, such as the peripheral blood mononuclear cells (PBMCs) in 
blood samples (30, 31) and squamous epithelial cells in urine samples (32, 33).
Somatic cells growing in tissue culture are first reprogrammed into iPSCs. This is 
accomplished through the transient, forced expression of transcription factors. Yamanaka’s 
breakthrough came with discovery that forced expression of four transcription factors, 
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commonly expressed in pluripotent cells, sufficiently “reprogramed” differentiated cells 
back to pluripotency (10). These four factors (OCT4, SOX2, KLF4 and c-MYC,) are termed 
the Yamanaka factors. While Yamanaka and his colleagues initially utilized retroviral 
transduction of these reprogramming factors, various techniques were soon developed to 
increase reprogramming efficiency and minimize vector integration into the host genome. A 
number of reprogramming methods and commercially available reprogramming kits are now 
available (34). Latest methods differ in terms of number of reprogramming factors utilized 
(usually between 2 and 4), level of efficiency, factor exposure time, and level of integration 
into the host genome.
A popular method utilizes cellular transfection, often by electroporation, of a nonintegrating 
episomal plasmid containing the reprogramming factors(30, 31, 35). The nonintegrating 
reprogramming plasmid is undetectable after multiple passages. This method requires 
altered culture media, and reprogramming efficiency is often low. Another increasingly 
popular method utilizes a Sendai Virus for transfection into the cell cytoplasm(36). The 
genetic material of the RNA virus does not enter the nucleus, nor integrate into the host 
genome, thus leaving all traces of virus undetectable after multiple rounds of passaging. 
Adenovirus is another non-integrating virus presenting attractive an option, although its 
current reprogramming efficiency is low(37).
Transient expression of reprogramming factor mRNA is an excellent, completely integration 
free, strategy (38). However, this method is labor intensive, requiring multiple days of 
mRNA exposure, and efficiency is often low. An additional strategy utilizes expression of 
reprogramming factor proteins; but these proteins are difficult to synthesize and purify, and 
the structures are large and charged, limiting plasma membrane diffusion(39). Other 
methods involve transdifferentiating to desired cell types following transient passage 
through an iPSC – like stage, rather than via full reprogramming(40, 41). This method is 
useful only if one, terminally differentiated cell type is required.
Particular somatic cells types are particularly senescent, difficult to reprogram, and require 
more rigorous reprogramming methods, or alternative methods to increase efficiency. There 
are methods with higher efficiency utilizing integrative reprogramming. A Cre-Lox system 
or transposon can be utilized to excise the reprogramming factors at a later date, if 
needed(42). Alternate strategies to increase reprogramming efficiency include: adding 
valproic acid and sodium butyrate to inhibit histone deacetylase, adding vitamin C as an 
antioxidant, cell culture in hypoxic conditions, and adding small molecule inhibitors of 
transforming growth factor beta (TGF-B) or rho-associated protein kinase (ROCK) (43–48).
Reprogramming methods vary in duration of time to reprogram, reprogramming efficiency, 
level of integration, and the time to loss of the reprograming vector or plasmid. Integration 
free methods are vital if derived tissue will ever be utilized for therapy. Selection of a 
method requires consideration of the somatic cell type being utilized, including current 
published methods, and the ultimate goal of the experiment. With a combination of these 
methods, almost all somatic tissue types can be successfully reprogrammed to iPSCs.
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Once iPSC culture is established, differentiation to almost any cell or tissue is possible. 
Differentiation usually involves initial differentiation to one of the three germ layers, 
ectoderm, mesoderm or endoderm, followed by further differentiation into a specific cell 
type. Differentiating iPSCs into terminally differentiated, clinically relevant cell types, 
utilizes protocols that often mimic the developmental pathways operant during 
embryogenesis. We highlight some of the major steps towards differentiation, whereas each 
particular cell type requires specific cell culture conditions, timing, and small molecule 
exposure (49, 50)(Figure 1).
Organoids
Sometimes a simple, two-dimensional iPSC-derived tissue culture model cannot fully 
recapitulate complex organ systems involving three-dimensional (3D) architecture; such 
cases necessitate organoid modeling. In vitro organogenesis, the exciting new frontier in in 
vitro disease modeling, aims to organize iPSCs into 3D structures that better recapitulate in 
vivo physiology (Table 2)(51, 52). Previous attempts at organoid modeling utilized primary 
tissue cells, but primary cells are difficult to obtain and often fails to propagate in vitro. In 
principle, iPSCs are an ideal cell source to make tissue organoids. The most comprehensive 
organoid model to date involves a fully vascularized and functional human liver (53). A 3D 
gastric organoid was created that progresses through developmental stages adopts similar 
architecture to the stomach (54). This organoid provided valuable insights into the gut 
development, as well as H. Pylori infection (55). Human iPSCs were grown also on rat 
intestinal matrix, to engineer a humanized intestinal graft for nutrient absorption in patients 
with short bowel syndrome (21). The established protocol for generating 3D cerebral 
organoids from iPSCs, replicates brain developmental stages. The organoid reproduces a 
variety of brain structures, including the cerebral cortex, ventral telencephalon, choroid 
plexus and retina (56). Manipulating specific developmental signaling pathways in ventral-
anterior foregut spheroids recently generated an iPSC-based human lung model (47). Lastly, 
an iPSC-based human kidney organoid model was recently developed displaying 
glomerulus-like structures and renal tubules (57). Future in vitro organogenesis effort must 
address the need for chemically defined synthetic extracellular matrices (ECMs), and 
incorporation of support cell types such as interspersed neurons, immune cells, and other 
regulatory cells. While the regenerative medicine field is still in infancy, transplantation of 
functional tissues derived from patient’s own cells could profoundly improve the health of 
patients with end-organ failure.
Large Scale Biorepositories
With the rapid development of iPSC disease models around the world, there are now 
multiple large-scale efforts to establish well-characterized biorepositories of disease specific 
iPSCs lines. The largest involved the New York Stem Cell Foundation (NYSCF), California 
Institute for Regenerative Medicine (CIRM), Human Induced Pluripotent Stem Cells 
Initiative (HipSci) and Stem cells for Biological Assays of Novel drugs and prediCtive 
toxiCology (StemBANCC)(58–61). These biorepositories are meant to increase 
collaboration and accelerate progress.
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Disease Models
Human iPSC disease models have been developed in nearly every organ system. Numerous 
diseases have been modeled utilizing iPSCs from mice, but we focus on human derived 
models. A number of excellent review articles have summarized iPSC disease modeling(62–
76); here we focus on common pediatric disorders and adult disorders with congenital and 
genetic etiology. We highlight some of the established disease models in each organ system 
and provide a more comprehensive list of disease models (Table 1).
Cardiac disease
Some of the earliest iPSC disease models were for cardiovascular disorders. Cardiac disease 
modeling with iPSC-derived cardiomyocytes has been highly successful; this is because 
iPSCs easily differentiate to cardiomyocytes, and many disease states result from altered 
cardiomyocyte function. Cardiac diseases, such as cardiomyopathies, mitochondriopathies, 
and channelopathies have been successfully modeled; whereas congenital heart diseases 
involving structural malformations require further refinement.
Congenital Long QT Syndrome (LQTS) was one of the first diseases modeled using patient-
derived iPSCs (77–79). (66–68). Congenital LQTS is an inherited condition, marked by 
aberrant repolarization and resultant cardiac arrhythmias. iPSC models of both type 1 and 2 
LQTS, due to KCNQ1 and KCNH2 gene mutations respectively, successfully recapitulate 
the prolonged repolarization phenotype. Pharmacotherapy, including nifedipine and 
pinacidil, reversed phenotype. Gene therapy has been utilized to generate a LQTS models 
(80), and to correct the mutation and restore electrophysiology in an iPSC-CM model of 
Brugada Syndrome (personal communication).
In addition, iPSC-CMs models have been developed for multiple inherited 
cardiomyopathies, including, familial dilated cardiomyopathy (DCM), hypertrophic 
cardiomyopathy (HCM), mitochondrial cardiomyopathy and arrhythmogenic right 
ventricular cardiomyopathy (ARVC) (80–83). In many familial dilated cardiomyopathy 
(DCM), specific sarcomere defects in cardiomyocytes lead to ventricular dilation and 
impaired contractile function; whereas in HCM, a different set of defects in the same 
sarcomere components lead to ventricular thickening and impaired relaxation. The iPSC-CM 
based models of DCM and HCM have provided valuable insight into how specific mutations 
in the sarcomere genes result in structural and functional defects observed in patients. 
Moreover, gene editing techniques have been used in iPSC-CM models to correct causal 
mutations and reverse cardiomyopathy (84). Beyond structural diseases, an iPSC-based 
model of viral cardiomyopathy due to Coxsackivurs infection was used to evaluate antiviral 
therapies (85). Other iPSC-based cardiac disease models include Pompe’s disease, Fabry 
disease, catecholaminergic polymorphic ventricular tachycardia, Timothy Syndrome, 
Leopard Syndrome, and Noonan Syndrome (86–90).
Hematologic Disease
In principle, hematologic disorders are well suited for modeling with iPSCs, given 
involvement of one cell type, easily derived from iPSCs, and unaffected by secondary 
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structure or organ architecture. Sickle Cell Disease (SCD) is a group of inherited blood 
disorders that cause great misery worldwide. The disease results from a single point 
mutation to the β-globin gene. This single mutation results in a truncated hemoglobin 
protein S with diminished oxygen carrying capacity and propensity to aggregate, causing 
pain and end organ damage. The NIH funded a large, comprehensive, and ethnically diverse 
library of SCD iPSCs lines for detailed in vitro study. In iPSC disease models, the SCD 
mutation has been corrected (91, 92). (80, 81).
Chronic Granulomatous Disease (CGD) is a genetically heterogeneous immunodeficiency 
marked by impaired neutrophil function and consequent susceptibility to certain bacterial 
and fungal infections. Various iPSC disease models accurately recapitulate the CGD 
phenotype. Further, a mutation was corrected in an CGD iPSC model resulting in recovery 
of neutrophil function (93, 94). Severe Combined Immunodeficiency (SCID) is another 
genetically heterogeneous immunodeficiency marked by defective differentiation of 
functional T cells and B cells. One form of SCID, caused by a mutation in Janus family 
kinase JAK3 gene was successfully modeled in vitro, when iPSCs demonstrated defective T 
cell differentiation.
The defect was subsequently corrected using CRISPR-Cas9 (22).
Hemophilia A and B are bleeding disorders caused by factor VIII deficiency. They have 
been effectively modeled with iPSCs and corrected in iPSC in vitro (95–98). Thalassemia 
and Fanconi Anemia have been modeled with iPSCs, and the Thalassemia in vitro 
phenotype has been reversed with the gene editing (99–101)These models open the door to 
new therapies, including an unlimited source of healthy, gene corrected, iPSC-derived, 
hematopoietic cells.
Neurologic Diseases
Historically, human neurologic diseases have been difficult to model in vitro given the 
inherent complexity of neural networks, and the inability to sample human brain and 
nervous tissues. Therefore iPSC-based models offer tremendous potential. Neurologic 
diseases result from defects in multiple nervous system cell types including neurons, 
astrocytes, and glial cells. Most of these relevant cell types can be generated using current 
iPSC differentiation protocols. Advances in tissue engineering may soon provide organoid 
models of the complex cell networks comprising the brain, spinal cord and peripheral 
nervous system.
Parkinson’s disease (PD) is a devastating illness marked by progressive deterioration of the 
dopaminergic neurons, leading to motor and cognitive declines. PD is caused by complex 
interaction between inherited genetic susceptibility and environmental exposures. 
Dopaminergic neurons derived from PD patients retain this complex genetic background, 
and successfully recapitulate the disease phenotype (102, 103). iPSC lines are helping to 
advance understanding of inherited and sporadic disease pathogenesis (104). In iPSC lines 
harboring different familial mutations implicated in PD, pharmacologic interrogation 
provided insight into the convergent cellular pathways involved in pathogenesis (105). Gene 
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correction of the mutations in diseased iPSCs reverses the abnormal dopaminergic neuronal 
phenotype (106).
Amyotrophic Lateral Sclerosis (ALS) is a condition marked by progressive deterioration of 
upper and lower motor neurons in the brain and spinal cord. Motor neurons derived from 
affected patient iPSCs effectively model ALS phenotype. The model has provided insight 
into disease pathogenesis, and proven useful for screening drug candidates (107–113). 
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder affecting voluntary 
skeletal muscles. SMA was one of the first genetic disorders successfully modeled using 
iPSCs (114–118), which replicate SMA’s affect on the neuromuscular junction (115). Lastly, 
Alzheimer’s Disease (AD) is a neurodegenerative disorder marked by progressive cognitive 
decline in later life. Etiology of this condition is multifactorial, involving both complex 
genetic inheritance, and environmental influences. Patient-derived iPSC lines have been used 
to differentiate between inherited and sporadic cases. They will play an important role in 
elucidating the myriad of contributors to AD (22, 119, 120).
Psychiatric disorders, including schizophrenia and bipolar disorder, have been modeled 
utilizing iPSCs. Schizophrenia is a complex and devastating psychiatric disease marked by 
development of psychosis in early adulthood. Etiology is likely multifactorial, resulting from 
genetic susceptibility as well as environmental influences. The disease affects 
neurobehavioral function at the highest levels, and its complex genetic influences make 
development of a valid animal model very challenging, if not impossible. In the context of 
this critical knowledge gap, schizophrenia patient iPSC-derived neurons have provided 
insight into disease pathogenesis, identifying genetic risk factors and altered signaling 
pathways (121–126). Interestingly, specific phenotypic markers, such as decreased neuronal 
connectivity and lower glutamate expression, were reversed in iPSC models of 
schizophrenia upon exposure to antipsychotic pharmacotherapy(127). In addition, an iPSC 
model of bipolar disorder demonstrated altered neurogenesis and neuroplasticity, and the 
phenotype recovered with pharmacologic rescue (128). Another bipolar model showed 
differential response to the commonly prescribed bipolar medication, lithium (129). Both 
bipolar iPSC findings may be valuable for developing new therapies and tailoring existing 
therapies.
Rett Syndrome is a severe neurodevelopmental disorder caused by mutations in the MECP2 
gene. iPSC neurons derived from affected patients exhibited phenotypic differences such as 
smaller soma size, fewer synapses, and abnormal signaling in comparison to controls (119, 
120). Pharmacological intervention rescued the synaptic abnormalities and identified a 
potential developmental window for therapeutic response.
Ongoing advances in iPSC-derived brain organoids more accurately model complex brain 
architecture. They will have profound impact on the study of human neurodevelopmental 
disorders, including microcephaly and autism(56).
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Digestive and Pulmonary System
iPSC-derived tissues have been developed to model a number of gastrointestinal (GI) and 
pulmonary diseases. For example, Wilson’s disease is a copper transport disorder affecting 
the liver and other organs. Copper accumulation leads to end organ damage. iPSC-derived 
hepatocytes from a patient with Wilson’s disease exhibited the pathognomonic copper 
transport defect, and the phenotype reversed with expression of the wild-type protein (130). 
Alpha-1 antitrypsin (A1AT) deficiency is a condition of defective α-1 antitrypsin function, 
leading to pulmonary deterioration and liver cirrhosis. iPSC-derived hepatocytes from a 
A1AT deficiency patient recapitulated many of the cellular features of the A1AT deficiency; 
these affects were also reversed by gene correction (131). Patient iPSC-derived hepatocytes 
have been used to model a number of other disorders, including various familial 
hypercholesterolemia and glycogen storage diseases (132). An iPSC-derived endodermal 
cell model recently provided insight into the familial pulmonary hypertension (133). In 
addition to these cellular disease models, iPSC-derived organoids hold great promise for the 
study of GI and pulmonary diseases.
Endocrine System
In principle, iPSC technology can be utilized to model every organ of the endocrine system, 
but here we focus on the pancreas and thyroid. Diabetes is characterized by elevated blood 
glucose due to absolute and relative deficiency of the hormone insulin. Diabetes leads to 
significant long-term sequelae and is a current global health epidemic. Normally, the 
pancreatic islet cells respond to elevated blood glucose levels with insulin production and 
release, tightly maintaining glucose homeostasis. While insulin therapy has been 
transformative, it has been difficult to accomplish the exquisite regulation of blood glucose 
achieved by the pancreas. Islet cell transplantation from deceased human donors have shown 
potential for tighter glucose control, but these cells are difficult to access and maintain (134, 
135). These limitations motivate efforts to develop functioning islets from iPSCs (29).
The thyroid gland follicular cells produces thyroid hormone, which affects almost every 
system in the body. Functional thyroid follicles have been generated from embryonic stem 
cells, and work is under way using patient-derived iPSCs (136). iPSC-derived thyroid 
progenitor cells were generated from individuals with hypothyroidism, as well as healthy 
controls, providing insight into thyroid development and dysfunction (137).
Renal System and Multisystem Disorders
The kidney has an essential role in electrolyte and fluid balance, waste removal and acid-
base status. These functions are sustained by the kidney’s complex structure, comprised of 
multiple cell types. While dialysis and transplantation can be life-saving in end-stage kidney 
failure, these treatment modalities require tremendous resources, and have significant 
inherent limitations. Human iPSC-derived kidney cells (iPSC-KCs) have significant 
potential for disease modeling and regeneration. While it is currently unknown whether 
iPSC-KCs can reconstitute all of kidney physiology in vitro, studies indicate that these cells 
can self-organize into kidney organoids containing cell populations with characteristics of 
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proximal tubules, podocytes and endothelium. The kidney organoids functionally 
recapitulate various aspects of renal epithelial physiology, and various kidney disease 
phenotypes. For instance, CRISPR-Cas9-mediated disruption of podocalyxin, a major 
constituent of the glycocalyx of the glomerular podocytes, leads to junctional defects in 
podocyte-like cells (115). In addition, disruption of the polycystic kidney disease genes 
PKD1 and PKD2 lead to pathognomonic cyst formation (138).
iPSC models have also been utilized to recapitulate multiorgan system disease. The 
multisystem disorder Trisomy 21, or Down Syndrome (DS), is one of the most common 
genetic disorders treated by Pediatricians. Trisomy 21 iPSC-derived neurons were found to 
have reduced synaptic activity, consistent with the DS physiology. These cell lines were 
utilized to highlight the role of astroglia in DS pathogenesis (139–141). In addition, Trisomy 
21 iPSCs exhibited abnormalities of the hematopoetic precursor-like cells (142). Recent 
studies demonstrated Hutchinson-Gilford Progeria (HGP) patient-derived iPSCs displayed 
differences in Progerin expression, and showed premature aging. These disease lines 
provided insight into HGP etiology (143, 144). By generating iPSCs from syndromic 
patients, and deriving multiple cell types, there is great potential for disease modeling and 
therapy in these complex multisystem disorders.
Limitations and Future Directions
In the short time since Yamanaka’s discovery and Nobel Prize, cellular reprogramming and 
iPSC technology have provided great insight into disease pathogenesis, and hope for 
regenerative therapies. Nonetheless, there remain a number of important limitations to the 
technology that necessitate further research and development. For instance, tissue sampling 
is particularly difficult in Pediatric patients, and future innovation should focus on non-
invasive tissue acquisition; this includes ever smaller amounts of blood samples and skin 
biopsies as well as improvement in reprogramming of epithelial cells from urine samples. 
Further improvements are needed in iPCS reprogramming efficiency, non-integrative 
reprogramming methods and patient safety. Efficiently generating mature and functional 
cells will require a better understanding of embryonic development and of intermediate cell 
types. Organoid or organs-on-a-chip technologies should be further developed to overcome 
extant limitations of two-dimensional cell culture models. Moreover, we need to further 
explore the impact reprogramming and tissue derivation on the epigenome. With continued 
advancements, iPSC technology holds great potential for regenerative medicine, tissue 
engineering, personalized therapies, disease modeling, toxicity monitoring and drug testing.
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Figure 1. 
A) To generate somatic tissue cultures, established protocols allow tissue sampling from skin 
fibroblasts, peripheral blood samples and urine sample. B) Reprogramming methods involve 
transient, forced expression of the four Yaminaka factors, Oct-4, Sox-2, Klf-4, c-Myc, C) 
ActivinA differentiates iPSCs to definitive and multipotent endoderm progenitors. 
Endoderm derivatives include anterior endoderm, multipotent lung progenitors, hindgut 
endoderm, intestinal tissue, hepatocytes, and pancreatic beta cells. D) iPSC induction with 
BMP4, FGF2 and ActivinA drives mesoderm derivatives including a primitive streak 
mesoderm, erythropoietic as well as lymphoid progenitors, osteoclasts, chondrogenic cells, 
adipogenic cells, smooth muscle cells, skeletal muscle cells, endothelial cells and 
cardiomyocytes. E) Neural progenitors become astrocytes, oligodendrocytes, cortical 
neurons, neural crest stem cells, spinal motor neurons, GABA neurons and DA neurons. 
Exposure to ascorbic acid and BMP4 differentiates iPSCs to keratinocytes then to epidermis. 
Nicotinamide induces retinal pigment epithelium and 3D culture of the cells creates an optic 
cup including a neural retinaiPSC are inducible to primordial germ cell-like cells, and 
further to oocyte-like cells, follicle-like cells, and spermatozoa.
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Table 1
iPSC Disease Models
Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
Long QT Synrome Cardiovascular Cardiomyocyte Itzhaki, Ilanlt, et al. 
“Modelling the long QT 
syndrome with induced 
pluripotent stem cells.” 
Nature 471.7337 (2011): 
225–229.
Wang, Yongming, 
et al. “Genome 
editing of isogenic 
human induced 
pluripotent stem 
cells recapitulates 
long QT 
phenotype for 
drug testing.” 
Journal of the 
American College 
of Cardiology 64.5 
(2014): 451–459.
Familial Dilated Cardiomyopathy Cardiovascular Cardiomyocyte Sun, Ning, et al. “Patient-
specific induced 
pluripotent stem cells as a 
model for familial dilated 
cardiomyopathy.” 
Science translational 
medicine 4.130 (2012): 
130ra47–130ra47. 1395–
1403.
Karakikes, 
Ioannis, et al. 
“Correction of 
human 
phospholamban 
R14del mutation 
associated with 
cardiomyopathy 
using targeted 
nucleases and 
combination 
therapy.” Nature 
communications 6 
(2015).
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)
Cardiovascular Cardiomyocyte Kim, Changsung, et al. 
“Studying 
arrhythmogenic right 
ventricular dysplasia with 
patient-specific iPSCs.” 
Nature 494.7435 (2013): 
105–110. ehs226.
Catecholaminergic polymorphic 
ventricular tachycardia (CPVT)
Cardiovascular Cardiomyocyte Jung, Christian B., et al. 
“Dantrolene rescues 
arrhythmogenic RYR2 
defect in a patient-
specific stem cell model 
of catecholaminergic 
polymorphic ventricular 
tachycardia.” EMBO 
molecular medicine 4.3 
(2012): 180–191.
Novak, Atara, et al. 
“ Cardiomyocytes 
generated from 
CPVTD307H patients are 
arrhythmogenic in 
response to β-adrenergic 
stimulation.” Journal of 
cellular and molecular 
medicine 16.3 (2012): 
468–482.
LEOPARD syndrome (lentigines, 
electrocardiographic abnormalities, 
ocular hypertelorism, pulmonary 
valve stenosis, abnormal genitalia, 
retardation of growth and deafness)
Cardiovascular Cardiomyocytes Carvajal-Vergara, Xonia, 
et al. “Patient-specific 
induced pluripotent stem-
cell-derived models of 
LEOPARD syndrome.” 
Nature 465.7299 (2010): 
808–812.
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
Timothy Syndrome (Long QT) Cardiovascular Cardiomyocytes Yazawa, Masayuki, et al. 
“Using induced 
pluripotent stem cells to 
investigate cardiac 
phenotypes in Timothy 
syndrome.” Nature 
471.7337 (2011): 230–
234.
Hypertrophic Cardiomyopathy Cardiovascular Cardiomyocytes Lan, Feng, et al. 
“Abnormal calcium 
handling properties 
underlie familial 
hypertrophic 
cardiomyopathy 
pathology in patient-
specific induced 
pluripotent stem cells.” 
Cell stem cell 12.1 
(2013): 101–113.
Sheng, Calvin C., 
et al. “Cellular and 
Cardiac 
Microtissue 
Assays of iPSC-
derived Myocytes 
With the 
Hypertrophic 
Cardiomyopathy 
Mutation in 
MYH7-
Val606Met.” 
(2015): A12532–
A12532.
Cardiac Na+ channel mutations Cardiovascular Cardiomyocytes Davis, Richard P., et al. 
“Cardiomyocytes derived 
from pluripotent stem 
cells recapitulate 
electrophysiological 
characteristics of an 
overlap syndrome of 
cardiac sodium channel 
disease.” Circulation 
(2012): 
CIRCULATIONAH 
A-111.
Mitochondrial Cardiomyopathy - 
Barth Syndrome
Cardiovascular Cardiomyocytes Wang, Gang, et al. 
“Modeling the 
mitochondrial 
cardiomyopathy of Barth 
syndrome with induced 
pluripotent stem cell and 
heart-on-chip 
technologies.” Nature 
medicine 20.6 (2014): 
616–623.
Pompe Disease Cardiovascular Cardiomyocytes Huang, Hsiang-Po, et al. 
“Human Pompe disease 
induced pluripotent stem 
cells for pathogenesis 
modeling, drug testing 
and disease marker 
identification.” Human 
molecular genetics 
(2011): ddr424.
Fanconi Anemia Blood Hematopoietic Cells Raya, Ángel, et al. 
“Disease-corrected 
haematopoietic 
progenitors from Fanconi 
anaemia induced 
pluripotent stem cells.” 
Nature 460.7251 (2009): 
53–59.
Sickle Cell Disease Blood Hematopoietic Cells Ye, Lin, et al. “Induced 
pluripotent stem cells 
offer new approach to 
therapy in thalassemia 
and sickle cell anemia 
Zou, Jizhong, et 
al. “Site-specific 
gene correction of 
a point mutation in 
human iPS cells 
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
and option in prenatal 
diagnosis in genetic 
diseases.” Proceedings of 
the National Academy of 
Sciences 106.24 (2009): 
9826–9830.
derived from an 
adult patient with 
sickle cell 
disease.” Blood 
118.17 (2011): 
4599–4608.
Sebastiano, 
Vittorio, et al. “In 
situ genetic 
correction of the 
sickle cell anemia 
mutation in human 
induced 
pluripotent stem 
cells using 
engineered zinc 
finger nucleases.” 
Stem cells 29.11 
(2011): 1717–
1726.
Thalassemia Blood Hematopoietic Cells Ye, Lin, et al. “Induced 
pluripotent stem cells 
offer new approach to 
therapy in thalassemia 
and sickle cell anemia 
and option in prenatal 
diagnosis in genetic 
diseases.” Proceedings of 
the National Academy of 
Sciences 106.24 (2009): 
9826–9830.
Xie, Fei, et al. 
“Seamless gene 
correction of β-
thalassemia 
mutations in 
patient-specific 
iPSCs using 
CRISPR/Cas9 and 
piggyBac.” 
Genome research 
24.9 (2014): 
1526–1533.
Type 1 Diabetes Endocrine islet beta cells Bar-Nur, Ori, et al. 
“Epigenetic memory and 
preferential lineage-
specific differentiation in 
induced pluripotent stem 
cells derived from human 
pancreatic islet beta 
cells.” Cell stem cell 9.1 
(2011): 17–23.
Ramiya, 
Vijayakumar K., et 
al. “Reversal of 
insulin-dependent 
diabetes using 
islets generated in 
vitro from 
pancreatic stem 
cells.” Nature 
medicine 6.3 
(2000): 278–282.
Hemophilia A Blood Modeling and gene 
correction
Park, Chul-Yong, et al. 
“Functional correction of 
large factor VIII gene 
chromosomal inversions 
in hemophilia A patient-
derived iPSCs using 
CRISPR-Cas9.” Cell 
Stem Cell 17.2 (2015): 
213-220.
Amyotrophic Lateral Sclerosis Nervous Motor Neurons Dimos, John T., et al. 
“Induced pluripotent 
stem cells generated from 
patients with ALS can be 
differentiated into motor 
neurons.” science 
321.5893 (2008): 1218–
1221.
Chronic granulomatous disease Blood Neutrophils Dowey, Linzhao Cheng, 
and Harry L. Malech. 
“Oxidase deficient 
neutrophils from X-
linked chronic 
granulomatous.” (2011).
Zou, Jizhong, et 
al. “Oxidase-
deficient 
neutrophils from 
X-linked chronic 
granulomatous 
disease iPS cells: 
functional 
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
correction by zinc 
finger nuclease-
mediated safe 
harbor targeting.” 
Blood 117.21 
(2011): 5561–
5572.
Familial Dysautonoimia Nervous Peripheral Neurons Lee, Gabsang, et al. 
“Modelling pathogenesis 
and treatment of familial 
dysautonomia using 
patient-specific iPSCs.” 
nature 461.7262 (2009): 
402–406.
Spinal Muscle Atrophy Nervous Motor neurons Ebert, Allison D., et al. 
“Induced pluripotent 
stem cells from a spinal 
muscular atrophy 
patient.” Nature 457.7227 
(2009): 277–280.
Schozophrenia Nervous Neurons Brain Organoid Brennand, Kristen J., et 
al. “Modelling 
schizophrenia using 
human induced 
pluripotent stem cells.” 
Nature 473.7346 (2011): 
221–225.
Alzheimer’s disease Nervous Neurons Israel, Mason A., et al. 
“Probing sporadic and 
familial Alzheimer/’s 
disease using induced 
pluripotent stem cells.” 
Nature 482.7384 (2012): 
216–220.
Yagi, Takuya, et al. 
“Modeling familial 
Alzheimer’s disease with 
induced pluripotent stem 
cells.” Human molecular 
genetics 20.23 (2011): 
4530–4539.
Kondo, Takayuki, et al. 
“Modeling Alzheimer’s 
disease with iPSCs 
reveals stress phenotypes 
associated with 
intracellular Aβ and 
differential drug 
responsiveness.” Cell 
stem cell 12.4 (2013): 
487–496.
Parkinson’s disease Nervous Dopaminergic neurons Sánchez-Danés, Adriana, 
et al. “Disease-specific 
phenotypes in dopamine 
neurons from human iPS-
based models of genetic 
and sporadic Parkinson’s 
disease.” EMBO 
molecular medicine 4.5 
(2012): 380–395.41ra90.
Sanders, Laurie 
H., et al. “LRRK2 
mutations cause 
mitochondrial 
DNA damage in 
iPSC-derived 
neural cells from 
Parkinson’s 
disease patients: 
reversal by gene 
correction.” 
Neurobiology of 
disease 62 (2014): 
381–386.
Rett Syndrome Nervous Neurons Marchetto, Maria CN, et 
al. “A model for neural 
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
development and 
treatment of Rett 
syndrome using human 
induced pluripotent stem 
cells.” Cell 143.4 (2010): 
527–539.
Autism Spectrum Disorder Nervous Neurons Prilutsky, Daria, et al. 
“iPSC-derived neurons as 
a higher-throughput 
readout for autism: 
promises and pitfalls.” 
Trends in molecular 
medicine 20.2 (2014): 
91–104.
Microcephaly Nervous Brain organoid Lancaster, Madeline A., 
et al. “Cerebral organoids 
model human brain 
development and 
microcephaly.” Nature 
501.7467 (2013): 373–
379.
Helicobacter Pylori Digestive Gastric organoid McCracken, Kyle W., et 
al. “Modelling human 
development and disease 
in pluripotent stem-cell-
derived gastric 
organoids.” Nature 
516.7531 (2014): 400–
404.
Laminopathies Multi-organ iPSCs Liu, Guang-Hui, et al. 
“iPSC Disease Modeling 
of Laminopathies.” 
Human iPS Cells in 
Disease Modelling. 
Springer Japan, 2016. 
53–67.
Liu, Guang-Hui, et 
al. “Targeted gene 
correction of 
laminopathy-
associated LMNA 
mutations in 
patient-specific 
iPSCs.” Cell stem 
cell 8.6 (2011): 
688–694.
Hutchinson-Gilford progeria Multi-organ neural progenitors 
endothelial cells fibroblasts 
VSMCs mesenchymal stem 
cells
Liu, Guang-Hui, et al. 
“Recapitulation of 
premature ageing with 
iPSCs from Hutchinson-
Gilford progeria 
syndrome.” Nature 
472.7342 (2011): 221–
225.
Gyrate Atrophy Nervous iPSCs Howden, Sara E., et al. 
“Genetic correction and 
analysis of induced 
pluripotent stem cells 
from a patient with gyrate 
atrophy.” Proceedings of 
the National Academy of 
Sciences 108.16 (2011): 
6537–6542.
Howden, Sara E., 
et al. “Genetic 
correction and 
analysis of 
induced 
pluripotent stem 
cells from a 
patient with gyrate 
atrophy.” 
Proceedings of the 
National Academy 
of Sciences 108.16 
(2011): 6537–
6542.
Duchenne muscular dystrophy 
(DMD)
Nervous Skeletal Muscles Salani, Sabrina, et al. 
“Generation of skeletal 
muscle cells from 
embryonic and induced 
pluripotent stem cells as 
Li, Hongmei Lisa, 
et al. “Precise 
correction of the 
dystrophin gene in 
duchenne 
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
an in vitro model and for 
therapy of muscular 
dystrophies.” Journal of 
cellular and molecular 
medicine 16.7 (2012): 
1353–1364.
muscular 
dystrophy patient 
induced 
pluripotent stem 
cells by TALEN 
and CRISPR-
Cas9.” Stem cell 
reports 4.1 (2015): 
143–154.
Hypothyroidism Endocrine Human thyroid progenitors Kurmann, Anita A., et al. 
“Regeneration of thyroid 
function by 
transplantation of 
differentiated pluripotent 
stem cells.” Cell stem cell 
17.5 (2015): 527–542.
Gaucher Disease Neurvous Neurons Awad, Ola, et al. “Altered 
TFEB-mediated 
lysosomal biogenesis in 
Gaucher disease iPSC-
derived neuronal cells.” 
Human molecular 
genetics 24.20 (2015): 
5775–5788.
Classical lissencephaly Nervous Cerebral Organoids Bershteyn, Marina, et al. 
“Human iPSC-Derived 
Cerebral Organoids 
Model Cellular Features 
of Lissencephaly and 
Reveal Prolonged Mitosis 
of Outer Radial Glia.” 
Cell Stem Cell (2017).
Noonan Syndrome Hypertrophic 
Cardiomyopathy
Cardiovascular Cardiomyocytes Jaffré, Fabrice, et al. 
“Generation of Raf1 
Mutant and Crispr-cas9 
Corrected Isogenic iPSC-
derived Cardiomyocytes 
to Model Hypertrophic 
Cardiomyopathy in 
Noonan Syndrome.” 
(2015): A397–A397.
Jaffré, Fabrice, et 
al. “Generation of 
Raf1 Mutant and 
Crispr-cas9 
Corrected Isogenic 
iPSC-derived 
Cardiomyocytes to 
Model 
Hypertrophic 
Cardiomyopathy 
in Noonan 
Syndrome.” 
(2015): A397–
A397.
Hereditary spastic paraplegia Nervous Neurons Denton, Kyle R., et al. 
“Loss of spastin function 
results in disease-specific 
axonal defects in human 
pluripotent stem cell-
based models of 
hereditary spastic 
paraplegia.” Stem cells 
32.2 (2014): 414–423.
Mitochondrial Metabolic Disorders Nervous neural progenitor cells Lorenz, Carmen, et al. 
“Human iPSC-derived 
neural progenitors are an 
effective drug discovery 
model for neurological 
mtDNA disorders.” Cell 
Stem Cell (2017).
Fragile X Syndrome Multi-organ FX-iPSCs Neurons Urbach, Achia, et al. 
“Differential modeling of 
Fragile X syndrome by 
human embryonic stem 
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Disease Organ System Derived Cell Type Leading Reference Gene Editing for 
Model or 
Correction
cells and induced-
pluripotent stem cells.” 
Cell stem cell 6.5 (2010): 
407.
α1-antitrypsin deficiency Digestive Hepatocyte like cells Tafaleng, Edgar N., et al. 
“Induced pluripotent 
stem cells model 
personalized variations in 
liver disease resulting 
from α1-antitrypsin 
deficiency.” Hepatology 
62.1 (2015): 147–157.
Yusa, Kosuke, et 
al. “Targeted gene 
correction of [agr] 
1-antitrypsin 
deficiency in 
induced 
pluripotent stem 
cells.” Nature 
478.7369 (2011): 
391–394.
Wilson’s Disease Multi-organ Hepatocytes Neurons Zhang, Shiqiang, et al. 
“Rescue of ATP7B 
function in hepatocyte-
like cells from Wilson’s 
disease induced 
pluripotent stem cells 
using gene therapy or the 
chaperone drug 
curcumin.” Human 
molecular genetics 20.16 
(2011): 3176–3187.
Zhang, Shiqiang, 
et al. “Rescue of 
ATP7B function in 
hepatocyte-like 
cells from 
Wilson’s disease 
induced 
pluripotent stem 
cells using gene 
therapy or the 
chaperone drug 
curcumin.” 
Human molecular 
genetics 20.16 
(2011): 3176–
3187.
Mitochondrial myopathy, 
encephalopathy, lactic acidosis, and 
stroke-like episodes (MELAS)
Nervous iPSCs Yahata, Naoki, et al. 
“TALEN-mediated shift 
of mitochondrial DNA 
heteroplasmy in MELAS-
iPSCs with m. 13513G> 
A mutation.” Scientific 
Reports 7.1 (2017): 
15557.
Yahata, Naoki, et 
al. “TALEN-
mediated shift of 
mitochondrial 
DNA 
heteroplasmy in 
MELAS-iPSCs 
with m. 13513G> 
A mutation.” 
Scientific Reports 
7.1 (2017): 15557.
Tuberous sclerosis Nervous iPSCs Armstrong, Laura C., et 
al. “Heterozygous loss of 
TSC2 alters p53 signaling 
and human stem cell 
reprogramming.” H uman 
Molecular Genetics 26.23 
(2017): 4629–4641.
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Table 2
Major Human Organoid Models
Organ System Disease Models Reference
Liver Alagille Syndrome Cystic 
Fibrosis
Takebe, Takanori, et al. “Vascularized and functional human liver from an iPSC-derived 
organ bud transplant.” Nature 499.7459 (2013): 481–484.
Brain -
 Cerebrum
 Cerebellum
 Hippocampus
Microcephaly
Autism
Schizophrenia
Lancaster, Madeline A., et al. “Cerebral organoids model human brain development and 
microcephaly.” Nature 501.7467 (2013): 373-379.
Intestine Cancer
Cystic Fibrosis
Short Bowel Syndrome
Watson, Carey L., et al. “An in vivo model of human small intestine using pluripotent 
stem cells.” Nature medicine 20.11 (2014): 1310–1314.
Kitano, Kentaro, et al. “Bioengineering of functional human induced pluripotent stem 
cell-derived intestinal grafts.” Nature Communications 8.1 (2017): 765.
Kidney Takasato, Minoru, et al. “Kidney organoids from human iPS cells contain multiple 
lineages and model human nephrogenesis.” Nature 526.7574 (2015): 564–568.
Stomach H. Pylori Peptic Ulcer Cancer McCracken, Kyle W., et al. “Modelling human development and disease in pluripotent 
stem-cell-derived gastric organoids.” Nature 516.7531 (2014): 400-404.
Lungs Cystic Fibrosis 
Bronchopulmonary Dyplasia
Dye, Briana R., et al. “In vitro generation of human pluripotent stem cell derived lung 
organoids.” Elife 4 (2015): e05098.
Pediatr Res. Author manuscript; available in PMC 2018 November 30.
